Ironwood and Forest plan to file linaclotide next year after positive Phase III results
This article was originally published in Scrip
Executive Summary
Ironwood Pharmaceuticals and Forest Laboratories will file their investigational drug linaclotide in the US in the third quarter of next year, for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC), following the success of the final Phase III trial in the drug's Phase III programme for these indications.